Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 17/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13696878 | 0.89 | PTGER1 (0.44) | PTGER1TBXA2RPPARGPTGER3CYP2C9 | |
| SCHEMBL4162462 | 0.89 | PTGER1 (0.67) | PTGER1TBXA2RPPARGPTGER3CYP2C9 | |
| SCHEMBL4155131 | 0.88 | PTGER1 (0.54) | PTGER1TBXA2RPPARGPTGER3CYP2C9 | |
| SCHEMBL13696813 | 0.86 | PTGER1 (0.60) | PTGER1TBXA2RPPARGPTGER3CYP2C9 | |
| SCHEMBL4151462 | 0.86 | PTGER1 (0.60) | PTGER1TBXA2RPPARGPTGER3CYP2C9 | |
| SCHEMBL5620087 | 0.86 | PTGER1 (0.63) | PTGER1TBXA2RCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4914240 | 0.86 | PTGER1 (0.51) | PTGER1TBXA2RPPARGPTGER3CYP2C9 | |
| SCHEMBL4166969 | 0.86 | PTGER1 (0.64) | PTGER1CYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL5620036 | 0.86 | PTGER1 (0.57) | PTGER1TBXA2RPPARGPTGER3CYP2C9 | |
| SCHEMBL4166988 | 0.85 | PTGER1 (0.61) | PTGER1TBXA2RPPARGPTGER3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | PTGER1 246/4885TBXA2R 10/4885PPARG 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.